Metformina Almus

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformina Almus (Metformin Hydrochloride)

Q: What is Metformina Almus used for?

Metformina Almus contains metformin hydrochloride and is used to improve blood‑sugar control in adults with type 2 diabetes mellitus. It helps lower both fasting and post‑prandial glucose levels as part of a comprehensive diabetes management plan that includes diet and exercise.

Q: How does Metformin Hydrochloride work?

Metformin Hydrochloride reduces hepatic glucose production by inhibiting mitochondrial complex I and activates AMP‑activated protein kinase (AMPK). This dual action decreases the amount of glucose released by the liver and increases the sensitivity of muscle and fat cells to insulin, facilitating greater glucose uptake.

Q: What is the usual dose of Metformina Almus?

The exact dose of Metformina Almus is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic targets, and tolerability. Initiation typically starts at a low dose, which may be titrated upward as needed, but the specific regimen should always follow the prescriber’s instructions.

Q: Is Metformina Almus safe during pregnancy or breastfeeding?

Safety of metformin in pregnancy and lactation has not been definitively established. It may be used during pregnancy only if the potential benefits outweigh the risks, and breastfeeding mothers should consult their physician, as metformin does pass into breast milk in small amounts.

Q: How do I order Metformina Almus from GNH India?

To place an order, submit an enquiry on the Metformina Almus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Q: How does Metformina Almus compare with other antidiabetic drugs?

Metformina Almus (metformin) belongs to the biguanide class and is generally first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas or insulin, metformin works primarily by reducing hepatic glucose output rather than stimulating insulin secretion.

Q: How should Metformina Almus be stored?

Store Metformina Almus at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Q: How is Metformina Almus administered?

Metformina Almus is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with Metformina Almus?

The most serious adverse reaction is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or acute heart failure. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Q: Who should not use Metformina Almus?

Metformina Almus is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who have experienced lactic acidosis while on metformin therapy. It should also be used with caution in patients with liver disease or congestive heart failure.

Metformin Hydrochloride, the active ingredient in Metformina Almus, is a biguanide presented as a tablet for oral use. It lowers elevated blood glucose by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, making it a cornerstone therapy for adults diagnosed with type 2 diabetes mellitus.

GNH India supplies Metformina Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across European and global markets through robust quality‑assured manufacturing and reliable logistics.

Manufacturer / TM Owner

Almus S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformina Almus (metformin) is indicated for the management of hyperglycaemia within the type 2 diabetes mellitus therapeutic pathway.

Type 2 diabetes mellitus: improves glycaemic control by reducing fasting and post‑prandial glucose levels.

How It Works

Metformin Hydrochloride acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis and lowers hepatic glucose output. It also increases peripheral glucose uptake and utilization by enhancing insulin‑mediated activation of AMP‑activated protein kinase (AMPK), thereby improving insulin sensitivity in muscle and adipose tissue.

Side Effects

Metformina Almus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
Metallic taste in the mouth.
Mild headache.
Decreased appetite.
Weight loss.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal accumulation of lactic acid.
Severe hypoglycaemia when combined with other glucose‑lowering agents.
Hepatic dysfunction.
Allergic reactions: rash, pruritus, or angio‑edema.
Vitamin B12 deficiency with long‑term use.

Precautions & Warnings

Before initiating therapy, clinicians should assess renal function, hepatic status, and potential contraindications.

Renal function assessment: avoid use in patients with eGFR <30 mL/min/1.73 m².
Hepatic disease monitoring: use cautiously in active liver disease.
Cardiovascular status: monitor for signs of heart failure exacerbation.
Concomitant alcohol intake: advise limitation to reduce lactic acidosis risk.
Pregnancy and lactation: evaluate risk‑benefit ratio with a healthcare professional.
Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Metformina Almus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging.
Cimetidine: can increase metformin plasma concentrations.
Nucleoside reverse transcriptase inhibitors (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may mask hypoglycaemia symptoms.
Diuretics (loop or thiazide): can affect renal clearance of metformin.
Corticosteroids: may raise blood glucose, requiring dose adjustment.
ACE inhibitors/ARBs: monitor renal function when used together.

Frequently Asked Questions

Metformina Almus contains metformin hydrochloride and is used to improve blood‑sugar control in adults with type 2 diabetes mellitus. It helps lower both fasting and post‑prandial glucose levels as part of a comprehensive diabetes management plan that includes diet and exercise.

Metformin Hydrochloride reduces hepatic glucose production by inhibiting mitochondrial complex I and activates AMP‑activated protein kinase (AMPK). This dual action decreases the amount of glucose released by the liver and increases the sensitivity of muscle and fat cells to insulin, facilitating greater glucose uptake.

The exact dose of Metformina Almus is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic targets, and tolerability. Initiation typically starts at a low dose, which may be titrated upward as needed, but the specific regimen should always follow the prescriber’s instructions.

Safety of metformin in pregnancy and lactation has not been definitively established. It may be used during pregnancy only if the potential benefits outweigh the risks, and breastfeeding mothers should consult their physician, as metformin does pass into breast milk in small amounts.

To place an order, submit an enquiry on the Metformina Almus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metformina Almus (metformin) belongs to the biguanide class and is generally first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas or insulin, metformin works primarily by reducing hepatic glucose output rather than stimulating insulin secretion.

Store Metformina Almus at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metformina Almus is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or acute heart failure. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Metformina Almus is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who have experienced lactic acidosis while on metformin therapy. It should also be used with caution in patients with liver disease or congestive heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.